capecitabine has been researched along with Esophageal Squamous Cell Carcinoma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 5 (62.50) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Q; Guo, L; Liu, J; Shangguan, C; Shi, M; Shi, Y; Wu, J; Xi, W; Yang, H; Zhang, J; Zhou, C | 1 |
| Bai, Y; Bei, T; Cai, M; Cai, P; Guo, Q; He, H; Huang, M; Huang, Y; Luo, G; Su, X; Wang, Z; Xiang, J; Yang, G; Zhang, X; Zheng, Y; Zhong, J | 1 |
| Bateman, A; Byrne, JP; Grace, BL; Iveson, T; Jackson, A; Kelly, JJ; Noble, F; Pucher, PH; Rahman, SA; Rees, C; Underwood, TJ; Walker, RC | 1 |
| Bai, K; Chen, B; Chi, D; Guo, S; Hu, Y; Li, Q; Ma, H; Zhu, Y | 1 |
| Cho, J; Im, YH; Kang, D; Kim, K; Kim, SB; Lee, G; Na, KJ; Park, SI; Shim, YM; Yun, J; Zo, JI | 1 |
| Li, X; Lin, S; Lin, W; Lin, Y; Wang, H | 1 |
| Barham, CP; Blazeby, JM; Brookes, ST; Crosby, T; Donovan, JL; Falk, SJ; Griffin, SM; Hollingworth, W; Hollowood, AD; Krysztopik, R; Nicklin, J; Streets, CG; Strong, S; Titcomb, D; Wilson, C | 1 |
| Im, YH; Kim, M; Kim, S; Lee, J; Lee, SJ; Park, SH; Park, YH | 1 |
1 review(s) available for capecitabine and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoplasms; Stomach Neoplasms | 2022 |
5 trial(s) available for capecitabine and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial.
Topics: Capecitabine; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local | 2023 |
The efficacy of adjuvant chemotherapy with capecitabine and cisplatin after surgery in locally advanced esophageal squamous cell carcinoma: a multicenter randomized phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoplasm Staging | 2022 |
Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Taxoids | 2013 |
Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Feasibility Studies; Female; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Pilot Projects; Treatment Outcome | 2014 |
Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Retreatment; Treatment Outcome | 2015 |
2 other study(ies) available for capecitabine and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Hospital Mortality; Humans; Length of Stay; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Postoperative Complications; Propensity Score; Survival Rate; Treatment Outcome | 2020 |
Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Oxonic Acid; Pyridines; Retrospective Studies; Tegafur | 2021 |